Royalty Pharma Announces Proposal to Acquire Elan for $11/Share

RP Management, LLC ("Royalty Pharma") today announces that contact was made on Monday February 18, 2013 with the Chairman of the Board of Elan Corporation, plc

("Elan"), followed by a meeting then taking place on Wednesday February 20, 2013, at which an indicative proposal was made to acquire the entire issued and to be issued share capital of Elan (the "Proposal"). Royalty Pharma is proposing, on an indicative basis, to make an offer for Elan (the "Possible Offer") of US$11[1] for every Elan Share and every Elan ADS. While Royalty Pharma has not received a formal response to its Proposal and has been unsuccessful in its efforts to engage with Elan since making the Proposal, Royalty Pharma remains committed to working towards a recommended transaction. Royalty Pharma was, however, surprised by Elan's public announcement on Friday February 22, 2013 discussing Elan's standalone strategy but not addressing the fact that Elan had received Royalty Pharma's Proposal. Royalty Pharma's Proposal offers Elan Shareholders a simple and clear choice: Remain an investor in a company whose material assets (in the context of the assets of the Elan Group, taken